Xilio Therapeutics Inc Dossier - Source-backed chat

Xilio Therapeutics Inc

XLONASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value $9.83median of 2 methodsbased on filings through 31 Dec 2025

Market Price $9.05Price as of 30 Sep 2026

Near fair valueIntrinsic value is 9% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $59.6M

Enterprise Value −$71M

Shares Outstanding 6M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Xilio Therapeutics is a clinical-stage biotechnology company leveraging its proprietary tumor-selective masking technology to develop safer, highly potent immuno-oncology (I-O) therapies. By engineering molecules (antibodies, cytokines, and T cell engagers) that selectively activate within the protease-rich tumor microenvironment, Xilio aims to overcome the severe systemic toxicities that historically limit I-O treatments. Backed by high-profile strategic collaborations with Gilead Sciences and AbbVie, Xilio has significantly de-risked its platform, validated its masking technology, and secured a robust cash runway extending into early 2028. With key clinical milestones on the horizon—including the imminent IND submission for its bispecific PD-1/masked IL-2 candidate (XTX501) and upcoming development candidate nominations—Xilio presents a compelling, asymmetric risk-reward profile for biotechnology investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$20.00

Mean target$20.00

High · most bullish analyst$20.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.0020%

XTX501 encounters regulatory delays or safety concerns during the Phase 1 trial, or preclinical programs fail to meet development milestones. Gilead declines to license efarindodekin alfa in 2027, depriving Xilio of the $75 million option fee and forcing the company to seek highly dilutive equity financing or restrict its pipeline development as the cash runway approaches early 2028.

Base CaseCentral scenario

$20.0050%

Matches the consensus mean

Xilio successfully submits the IND for XTX501 in mid-2026 and initiates the Phase 1 trial in H2 2026. Preclinical development for the PSMA/STEAP1 and CLDN18.2 masked T cell engagers progresses on schedule toward IND submissions in 2027. The company maintains its cash runway into early 2028 through disciplined operational execution and the achievement of scheduled development milestones under the AbbVie and Gilead collaborations.

Bull CaseUpside scenario

$28.0030%

Gilead exercises its option to license efarindodekin alfa (masked IL-12) in H1 2027, triggering a $75 million option fee and substantial milestone payments. Concurrently, XTX501 demonstrates robust monotherapy activity and a superior safety profile in its Phase 1 trial, establishing it as a foundational backbone therapy for solid tumors. Preclinical programs with AbbVie advance rapidly, unlocking near-term milestone payments and extending the cash runway beyond 2029.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Clinically validated tumor-selective masking platform designed to expand the therapeutic index of potent I-O agents.
Strong validation and non-dilutive funding from major pharmaceutical partners, including Gilead Sciences and AbbVie.
Robust balance sheet with $150.3 million in cash as of March 31, 2026, providing an extended runway into early 2028.
Asymmetric valuation upside with multiple near-term clinical and regulatory catalysts through 2026 and 2027.

Key Investment Risks

High clinical development risk inherent to early-stage oncology pipelines.
Reliance on partner execution and opt-in decisions (specifically Gilead in H1 2027) for long-term funding and commercialization.
Potential for regulatory delays or clinical holds during IND submissions and Phase 1 trial initiations.
Intense competition in the immuno-oncology space from established therapies and alternative modalities.

Thesis Invalidation Triggers

Failure to submit the IND or obtain FDA clearance for XTX501 in 2026.
Gilead deciding not to exercise its option for the IL-12 program (efarindodekin alfa) in 2027.
Severe systemic toxicities (e.g., cytokine release syndrome) observed in clinical trials of masked candidates, undermining the core technology thesis.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.